Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | APP | P05067 | 5/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196924 | 0.91 | BACE1 (0.46) | CYP1B1BACE1MAPTKDM4ETLR2 | |
| SCHEMBL2800255 | 0.89 | BACE1 (0.41) | CYP1B1BACE1NCF1MAPTKDM4E | |
| SCHEMBL29455719 | 0.82 | BACE1 (0.46) | BACE1MAPTTLR2MEN1KMT2A | |
| SCHEMBL29455889 | 0.81 | BACE1 (0.45) | BACE1MAPTKDM4ETLR2MEN1 | |
| SCHEMBL16621225 | 0.81 | BACE1 (0.45) | BACE1NCF1MAPTTLR2MEN1 | |
| SCHEMBL16620820 | 0.79 | BACE1 (0.46) | BACE1NCF1MAPTKDM4ETLR2 | |
| SCHEMBL22117590 | 0.79 | BACE1 (0.46) | BACE1MAPTKDM4ETLR2MEN1 | |
| SCHEMBL22117596 | 0.79 | BACE1 (0.46) | BACE1MAPTKDM4ETLR2MEN1 | |
| SCHEMBL2802429 | 0.79 | MAPT (0.52) | CYP1B1BACE1NCF1MAPTAPP | |
| SCHEMBL2801588 | 0.77 | KDM4E (0.56) | NCF1MAPTAPPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (PA) | 2010-08-26 | — | — | US | disclosed |
| EP-2144916-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | The Trustees of the University of Pennsylvania (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008124812-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | APP, PSEN1, PSEN2 | CYP1B1 2285/4885BACE1 10/4885NCF1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.